FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system

Clinics

Volumn 68, Issue 7, 2013, Pages 1018-1027

  Pereira, Felipe V ^a   Arruda, Denise C ^a   Figueiredo, Carlos R ^a   Massaoka, Mariana H ^a   Matsuo, Alisson L ^a   Bueno, Valquiria ^a   Rodrigues, Elaine G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

catenin; Apoptosis; FTY720; Immunomodulation; Metastasis; Murine melanoma B16F10; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DRUG DERIVATIVE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; SPHINGOSINE;

ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; MALE; METASTASIS; METHODOLOGY; MOUSE; PATHOLOGY; TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; PROPYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; SPHINGOSINE; TIME FACTORS;

EID: 84881256674     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(07)21     Document Type: Article

References (40)

1. Kiuchi M, Adachi K, Tomatsu A, Chino M, Takeda S, Tanaka Y, et al. Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg Med Chem. 2005;13(2):425-32, http://dx.doi.org/10.1016/j.bmc.2004.10.008.
2. Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-bind study. Transplantation. 2007;84(7):885-92, http://dx.doi.org/10.1097/01.tp. 0000281385.26500.3b.
3. Commodaro AG, Pedregosa JF, Peron JPS, Brandão WN, Rizzo LV, Bueno V. The imbalance between Treg/Th17 cells caused by FTY720 treatment in skin allograft rejection. Clinics. 2012;67(7):805-13, http://dx. doi.org/10.6061/clinics/2012(07)17.
4. Pedregosa JF, Haidar AA, Hirata AE, Franco M, Gomes GN, Bueno V. TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720. Int Immunopharmacol. 2011;11(9):1311-8, http://dx.doi.org/10.1016/j.intimp.2011.04.014.
5. Papadoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res. 2010;88(2):346-59, http://dx.doi.org/10.1002/jnr.22196.
6. Commodaro AG, Perons JPS, Lopes CT, Arslanian C, Belfort R, Bueno V. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci. 2010;51(5):2568-74, http://dx.doi. org/10.1167/iovs.09-4769.
7. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 1999;40(1): 50-5, http://dx.doi.org/10.1002/(SICI)1097-0045(19990615)40:1,50::AIDPROS6.3.0 . CO;2-N.
8. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003;169(6):2372-7.
9. Lee TK, Man K, Ho JW, Sun CK, NgKT, Wang XH, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI2-K-mediated Akt dephosphorylation Carcinogenesis. 2004;25(12):2397-405.
10. Ubai T, Azuma H, Kotake Y, Inamoto T, Takahara K, Ito Y, et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cell in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res. 2007;27(1A):75-88.
11. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bedall LJ. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011;7(7):707-15, http://dx.doi.org/10. 4161/auto.7.7.15154
12. Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K, et al. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci. 2012;45(5):600-5.
13. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002;62:1410-9.
14. Liu Y, Deng J, Wang L, Lee H, Armstrong B, Scuto A, et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood. 2012;120(7):1458-65, http://dx.doi.org/10. 1182/blood-2011-12-399030.
15. Zhang N, Chen Y, Jiang R, Li E, Chen X, Xi Z, et al. PARP and RIP 1 are required for autophagy induced by 11'-deoxyverticillin A, which precedes caspase-dependent apoptosis. Autophagy. 2011;7(6):598-612, http://dx.doi.org/10.4161/auto.7.6.15103.
16. Matés JM, Segura JA, Alonso FJ, Márquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol. 2008;82(5):273-99, http://dx.doi.org/10. 1007/s00204-008-0304-z.
17. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005;117(6):1039-48.
18. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-06, http://dx.doi.org/10. 1200/JCO.2009.23.4799.
19. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) EORTC Melanoma Group. Eur J Cancer. 2011;47(10): 1476-83.
20. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16.
21. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. TRANSFORMS Study Group. N Engl J Med. 2010 4;362(5):402-15.
22. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-21, http://dx.doi.org/10.1172/ JCI31095.
23. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 2010;70(13):5438-47, http://dx.doi.org/10.1158/ 0008-5472.CAN-09-2544.
24. Salinas NR, Oshima CT, Cury PM, Cordeiro JA, Bueno V. FTY720 and lung tumor development. Int Immunopharmacol. 2009;9(6):689-93, http://dx.doi.org/10.1016/j.intimp.2008.12.007.
25. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66(1):221-31, http://dx.doi.org/10.1158/0008-5472.CAN-05-2001.
26. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2012;4(1):1-17.
27. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278(36):33714-23, http://dx.doi.org/ 10.1074/jbc.M302559200.
28. Liu MJ, Wang Z, Li HX, Wu RC, Liu YZ, Wu QY. Mitochondrial dysfunction as an early event in the process of apoptosis induced by woodfordin I in human leukemia K562 cells. Toxicol Appl Pharmacol. 2004;194(2):141-55, http://dx.doi.org/10.1016/j.taap.2003.08.017.
29. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619-42, http://dx.doi.org/10.1146/annurev.physiol.60.1.619.
30. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene. 2002;286(1):135-41, http://dx.doi.org/10.1016/S0378-1119(01)00814-9.
31. Herencia C, Martínez-Moreno JM, Herrera C, Corrales F, Santiago-Mora R, Espejo I, et al. Nuclear translocation of b-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One. 2012;7(4):e34656, http://dx.doi.org/10.1371/ journal.pone.0034656.
32. Miller JR, Moon RT. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev. 1996; 10(20):2527-39, http://dx.doi.org/10.1101/gad.10.20.2527.
33. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 1997;13(4):157-62, http:// dx.doi.org/10.1016/S0168-9525(97)01093-7.
34. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009;113(7):1513-21.
35. Olmeda D, Castel S, Vilaró S, Cano A. Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell. 2003;14(7):2844-60, http://dx.doi.org/10.1091/mbc.e03",-1, "xxx/mbc.e03-01-0865.
36. Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, et al. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer. 2005;113(3):415-22.
37. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009;106(4):1193-8, http:// dx.doi.org/10.1073/pnas.0811902106.
38. Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res. 2008;14(18):5825-32, http://dx. doi.org/10.1158/1078-0432.CCR-07-5104.
39. Hansen W, Hutzler M, Abel S, Alter C, Stochmann C, Kliche S, et al. Nueropilin 1 deficienty on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001-16, http://dx. doi.org/10.1084/jem.20111497.
40. Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011;118(26):6893-903, http:// dx.doi.org/10.1182/blood-2011-06-363879.